+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Predictive Biomarkers Market - Global Forecast 2026-2032- Product Image
Predictive Biomarkers Market - Global Forecast 2026-2032- Product Image
Sale

Predictive Biomarkers Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6279768
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Predictive Biomarkers Market is projected to reach USD 30.89 Billion in 2026. It is expected to continue growing at a CAGR of 17.61%, reaching USD 82.74 Billion by 2032.

Predictive Biomarkers: Introduction and Strategic Significance

Predictive biomarkers are measurable biological characteristics used to anticipate how a patient is likely to respond to a specific therapy. They support treatment selection, clinical-trial enrichment, companion-diagnostic development, and more individualized care across oncology, immunology, infectious disease, and other therapeutic areas. Their value depends on analytical validity, clinical validity, clinical utility, reproducibility, and integration into real-world workflows.

Transformative Shifts Reshaping Predictive Biomarker Development

The field is shifting from single-analyte testing toward multimodal approaches that combine genomic, transcriptomic, proteomic, pathological, and clinical information. Broader sequencing access, digital pathology, liquid-biopsy research, and decentralized sample collection are expanding the range of measurable signals. At the same time, regulators, payers, laboratories, and healthcare providers are placing greater emphasis on evidence quality, test standardization, interoperability, turnaround time, and equitable access.

How Artificial Intelligence Is Changing Predictive Biomarker Workflows

Artificial intelligence is being applied to identify candidate biomarkers, interpret complex molecular profiles, analyze medical images, stratify trial participants, and support treatment-response prediction. Its practical contribution is strongest when models are trained on representative, well-annotated data and validated across institutions and patient populations. Key safeguards include transparent performance reporting, bias assessment, human oversight, data governance, cybersecurity, and prospective evaluation before routine clinical use.

Regional Insights Across Predictive Biomarker Ecosystems

North America benefits from advanced translational research, established molecular-testing infrastructure, and active links between drug development and diagnostics. Europe emphasizes coordinated evidence generation, data protection, laboratory quality, and cross-border regulatory alignment. Asia-Pacific combines strong research capacity in several markets with substantial variation in laboratory access, reimbursement, and clinical standardization. Latin America is expanding precision-medicine capabilities while continuing to address infrastructure, affordability, and workforce constraints. The Middle East is investing in genomics, specialized healthcare, and national data programs, whereas Africa presents significant unmet need alongside emerging genomic initiatives and uneven access to validated testing.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets show diverse levels of molecular-testing maturity, creating opportunities for shared standards, regional referral networks, and workforce development. BRICS economies combine major patient populations and research capabilities with differences in regulatory systems, funding, and access. The European Union benefits from coordinated scientific and regulatory frameworks, although implementation remains heterogeneous across member states. G7 countries generally have mature clinical-research ecosystems and stronger laboratory infrastructure, while still confronting cost, interoperability, and population-representation challenges. GCC countries are strengthening precision-health capacity through centralized investment and specialized care. NATO members vary widely in healthcare organization but share interest in resilient biomedical supply chains, secure health data, and advanced research collaboration.

Country Insights: Market Readiness and Evidence Priorities

The United States and Canada have broad translational research and testing capabilities, with continued focus on reimbursement, evidence standards, and access disparities. The United Kingdom, France, Germany, Italy, and Spain are advancing precision medicine within structured public-health systems, while addressing differing adoption pathways and laboratory coordination. China, Japan, South Korea, India, and Australia combine sophisticated research activity with varying population diversity, regulatory processes, and access across urban and rural settings. Brazil, Mexico, and Russia are developing capabilities amid differences in healthcare financing, infrastructure, and availability of specialized testing. Across all countries, priorities include locally representative validation, standardized preanalytics, clinician education, and integration of results into treatment pathways.

Actionable Priorities for Predictive Biomarker Leaders

Leaders should define the clinical decision a biomarker is intended to improve before selecting technologies or endpoints. They should build evidence plans spanning analytical validation, clinical performance, utility, health-economic value, and post-deployment monitoring. Interoperable data architectures, quality-controlled laboratory networks, and partnerships among clinicians, diagnostic specialists, researchers, regulators, and patient groups can improve implementation. Organizations should also use diverse datasets, document model limitations, protect sensitive information, and design access strategies that account for geography, affordability, and health-system capacity.

Research Methodology for the Executive Summary

This summary uses a structured qualitative assessment of predictive-biomarker development and adoption, organized by technology, clinical workflow, evidence requirements, geography, and stakeholder group. Insights are grounded in established principles of biomarker validation, precision medicine, clinical diagnostics, artificial-intelligence governance, and healthcare implementation. Regional, group, and country comparisons are presented as contextual observations rather than quantitative rankings or market measurements. No market estimates, shares, forecasts, or company-specific claims are used.

Conclusion: Building Reliable and Equitable Predictive Biomarker Systems

Predictive biomarkers can make treatment selection more precise, improve trial design, and support more efficient use of healthcare resources when supported by rigorous evidence and dependable implementation. The next phase will depend less on discovery alone and more on reproducibility, multimodal validation, responsible artificial intelligence, interoperable infrastructure, and equitable access. Industry leaders that connect scientific innovation with clinical utility and trustworthy governance will be best positioned to translate biomarker insights into meaningful patient outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Predictive Biomarkers Market, by Biomarker Type
7.1. Introduction
7.2. Genomic Biomarkers
7.2.1. DNA Mutations
7.2.2. Copy Number Alterations
7.2.3. Gene Rearrangements
7.3. Immunological Biomarkers
7.4. Proteomic Biomarkers
7.4.1. Protein Expression
7.4.2. Phosphoproteins
7.5. Epigenetic Biomarkers
7.6. Transcriptomic Biomarkers
7.6.1. mRNA Expression
7.6.2. microRNA
7.7. Metabolomic Biomarkers
7.7.1. Lipid Metabolites
7.7.2. Amino Acid Metabolites
8. Predictive Biomarkers Market, by Product
8.1. Introduction
8.2. Consumables
8.2.1. Assay Kits
8.2.2. Detection Kits
8.2.3. Reagents
8.3. Services
8.3.1. Biomarker Discovery
8.3.2. Biomarker Validation
8.3.3. Clinical Biomarker Testing
8.3.4. Assay Development
8.4. Instruments
8.4.1. Sequencing Systems
8.4.2. PCR Systems
8.4.3. Mass Spectrometry Systems
8.4.4. Immunoassay Analyzers
8.4.5. Imaging Systems
8.4.6. Flow Cytometry Systems
8.4.7. Microarray Systems
8.5. Software
8.5.1. Bioinformatics Platforms
8.5.2. AI Analytics
9. Predictive Biomarkers Market, by Analytical Technology
9.1. Introduction
9.2. Immunoassays
9.3. Next-Generation Sequencing
9.4. Polymerase Chain Reaction
9.5. Mass Spectrometry
9.6. Immunohistochemistry
9.7. Flow Cytometry
9.8. Microarray Analysis
9.9. Fluorescence In Situ Hybridization
9.10. CRISPR-based Diagnostic Platforms
10. Predictive Biomarkers Market, by Therapeutic Area
10.1. Introduction
10.2. Oncology
10.2.1. Lung Cancer
10.2.2. Breast Cancer
10.2.3. Colorectal Cancer
10.2.4. Prostate Cancer
10.2.5. Lymphoid Malignancies
10.2.6. Myeloid Malignancies
10.2.7. Melanoma
10.2.8. Ovarian Cancer
10.2.9. Pancreatic Cancer
10.3. Cardiovascular Diseases
10.4. Neurological Disorders
10.4.1. Alzheimer's Disease
10.4.2. Parkinson's Disease
10.5. Metabolic Disorders
10.5.1. Diabetes
10.5.2. Obesity
10.6. Autoimmune Diseases
10.7. Infectious Diseases
10.7.1. HIV
10.7.2. Hepatitis
10.8. Respiratory Diseases
10.9. Renal Diseases
11. Predictive Biomarkers Market, by Assay Configuration
11.1. Introduction
11.2. Multi-Biomarker Panels
11.3. Single-Biomarker Assays
12. Predictive Biomarkers Market, by Application
12.1. Introduction
12.2. Drug Development
12.3. Clinical Decision Support
12.4. Precision Medicine
12.5. Disease Risk Prediction
12.6. Pharmacogenomics
13. Predictive Biomarkers Market, by End User
13.1. Introduction
13.2. Pharmaceutical Companies
13.3. Clinical Laboratories
13.4. Biotechnology Companies
13.5. Academic and Research Institutions
13.6. Diagnostic Laboratories
13.7. Hospitals
13.8. Contract Research Organizations
14. Predictive Biomarkers Market, by Region
14.1. Introduction
14.2. North America
14.3. Europe
14.4. Asia-Pacific
14.5. Latin America
14.6. Middle East
14.7. Africa
15. Predictive Biomarkers Market, by Group
15.1. Introduction
15.2. NATO
15.3. G7
15.4. European Union
15.5. BRICS
15.6. ASEAN
15.7. GCC
16. Predictive Biomarkers Market, by Country
16.1. Introduction
16.2. United States
16.3. China
16.4. Germany
16.5. Japan
16.6. France
16.7. Italy
16.8. Canada
16.9. United Kingdom
16.10. Spain
16.11. India
16.12. Brazil
16.13. South Korea
16.14. Australia
16.15. Russia
16.16. Mexico
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. F. Hoffmann-La Roche Ltd
18.2. Thermo Fisher Scientific Inc.
18.3. Danaher Corporation
18.4. Tempus AI, Inc.
18.5. Labcorp Holdings Inc.
18.6. QIAGEN N.V.
18.7. Illumina, Inc.
18.8. Guardant Health, Inc.
18.9. Revvity, Inc.
18.10. Myriad Genetics, Inc.
18.11. Caris Life Sciences, Inc.
18.12. NeoGenomics, Inc.
18.13. Quest Diagnostics Incorporated
18.14. Natera, Inc.
18.15. Eurofins Scientific SE
18.16. Agilent Technologies, Inc.
18.17. IQVIA Holdings Inc.
18.18. Bio-Rad Laboratories, Inc.
18.19. Veracyte, Inc.
18.20. Oxford BioDynamics Plc
18.21. 10x Genomics, Inc.
18.22. Abbott Molecular, Inc.
18.23. Axe Compute Inc.
18.24. Biodesix, Inc.
18.25. bioMérieux Inc.
18.26. BostonGene Corporation
18.27. Bruker Corporation
18.28. Charles River Laboratories International, Inc.
18.29. Crown Bioscience, Inc.
18.30. MDxHealth SA
18.31. Metabolon, Inc.
18.32. OncoDNA SA
18.33. Owkin, Inc.
18.34. PathAI, Inc.
18.35. Personalis, Inc.
18.36. Quanterix Corporation
18.37. Standard BioTools Inc.
18.38. Sysmex Corporation
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Predictive Biomarkers Market, Years Considered for the Study
FIGURE 2. Global Predictive Biomarkers Market, Research Design
FIGURE 3. Global Predictive Biomarkers Market, Research Framework
FIGURE 4. Global Predictive Biomarkers Market, Data Triangulation
FIGURE 5. Global Predictive Biomarkers Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Predictive Biomarkers Market Size, by Biomarker Type, 2025 vs 2032 (%)
FIGURE 7. Global Predictive Biomarkers Market Size, by Biomarker Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Predictive Biomarkers Market Size, by Product, 2025 vs 2032 (%)
FIGURE 9. Global Predictive Biomarkers Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Predictive Biomarkers Market Size, by Analytical Technology, 2025 vs 2032 (%)
FIGURE 11. Global Predictive Biomarkers Market Size, by Analytical Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Predictive Biomarkers Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 13. Global Predictive Biomarkers Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Predictive Biomarkers Market Size, by Assay Configuration, 2025 vs 2032 (%)
FIGURE 15. Global Predictive Biomarkers Market Size, by Assay Configuration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Predictive Biomarkers Market Size, by Application, 2025 vs 2032 (%)
FIGURE 17. Global Predictive Biomarkers Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Predictive Biomarkers Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Predictive Biomarkers Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Predictive Biomarkers Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Predictive Biomarkers Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Predictive Biomarkers Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Predictive Biomarkers Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Predictive Biomarkers Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Predictive Biomarkers Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Predictive Biomarkers Market Segmentation & Coverage
TABLE 2. Global Predictive Biomarkers Market Size, 2017-2032 (USD Million)
TABLE 3. Global Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 4. Global Genomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Genomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Genomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global DNA Mutations Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global DNA Mutations Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global DNA Mutations Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Copy Number Alterations Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Copy Number Alterations Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Copy Number Alterations Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Gene Rearrangements Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Gene Rearrangements Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Gene Rearrangements Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Immunological Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Immunological Biomarkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Immunological Biomarkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Proteomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Proteomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Proteomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Protein Expression Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Protein Expression Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Protein Expression Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Phosphoproteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Phosphoproteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Phosphoproteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Epigenetic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Epigenetic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Epigenetic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Transcriptomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Transcriptomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Transcriptomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global mRNA Expression Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global mRNA Expression Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global mRNA Expression Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global microRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global microRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global microRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Metabolomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Metabolomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Metabolomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Lipid Metabolites Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Lipid Metabolites Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Lipid Metabolites Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Amino Acid Metabolites Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Amino Acid Metabolites Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Amino Acid Metabolites Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 50. Global Consumables Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Consumables Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Consumables Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Assay Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Assay Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Assay Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Detection Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Detection Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Detection Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Biomarker Discovery Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Biomarker Discovery Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Biomarker Discovery Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Biomarker Validation Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Biomarker Validation Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Biomarker Validation Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Clinical Biomarker Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Clinical Biomarker Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Clinical Biomarker Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Assay Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Assay Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Assay Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Sequencing Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Sequencing Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Sequencing Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global PCR Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global PCR Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global PCR Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Mass Spectrometry Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Mass Spectrometry Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Mass Spectrometry Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Immunoassay Analyzers Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Immunoassay Analyzers Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Immunoassay Analyzers Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Imaging Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Imaging Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Imaging Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Flow Cytometry Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Flow Cytometry Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Flow Cytometry Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Microarray Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Microarray Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Microarray Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Bioinformatics Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Bioinformatics Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Bioinformatics Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global AI Analytics Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global AI Analytics Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global AI Analytics Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 111. Global Immunoassays Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Immunoassays Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Immunoassays Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Next-Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Next-Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Next-Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 123. Global Immunohistochemistry Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Immunohistochemistry Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Immunohistochemistry Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global Flow Cytometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global Flow Cytometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global Flow Cytometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global Microarray Analysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Global Microarray Analysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. Global Microarray Analysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 132. Global Fluorescence In Situ Hybridization Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Global Fluorescence In Situ Hybridization Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. Global Fluorescence In Situ Hybridization Market Size, by Country, 2017-2032 (USD Million)
TABLE 135. Global CRISPR-based Diagnostic Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global CRISPR-based Diagnostic Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global CRISPR-based Diagnostic Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 139. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 154. Global Lymphoid Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Global Lymphoid Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. Global Lymphoid Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. Global Myeloid Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Myeloid Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Myeloid Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. Global Ovarian Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Global Ovarian Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. Global Ovarian Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 169. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 172. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 173. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 175. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 176. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 177. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 178. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 179. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 181. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 184. Global Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 185. Global Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. Global Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 187. Global Obesity Market Size, by Region, 2017-2032 (USD Million)
TABLE 188. Global Obesity Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. Global Obesity Market Size, by Country, 2017-2032 (USD Million)
TABLE 190. Global Autoimmune Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Global Autoimmune Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 192. Global Autoimmune Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 193. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 194. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 196. Global HIV Market Size, by Region, 2017-2032 (USD Million)
TABLE 197. Global HIV Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. Global HIV Market Size, by Country, 2017-2032 (USD Million)
TABLE 199. Global Hepatitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 200. Global Hepatitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 201. Global Hepatitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 202. Global Respiratory Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 203. Global Respiratory Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. Global Respiratory Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 205. Global Renal Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Global Renal Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. Global Renal Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 208. Global Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
TABLE 209. Global Multi-Biomarker Panels Market Size, by Region, 2017-2032 (USD Million)
TABLE 210. Global Multi-Biomarker Panels Market Size, by Group, 2017-2032 (USD Million)
TABLE 211. Global Multi-Biomarker Panels Market Size, by Country, 2017-2032 (USD Million)
TABLE 212. Global Single-Biomarker Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 213. Global Single-Biomarker Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 214. Global Single-Biomarker Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 215. Global Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
TABLE 216. Global Drug Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 217. Global Drug Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. Global Drug Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 219. Global Clinical Decision Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 220. Global Clinical Decision Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. Global Clinical Decision Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 222. Global Precision Medicine Market Size, by Region, 2017-2032 (USD Million)
TABLE 223. Global Precision Medicine Market Size, by Group, 2017-2032 (USD Million)
TABLE 224. Global Precision Medicine Market Size, by Country, 2017-2032 (USD Million)
TABLE 225. Global Disease Risk Prediction Market Size, by Region, 2017-2032 (USD Million)
TABLE 226. Global Disease Risk Prediction Market Size, by Group, 2017-2032 (USD Million)
TABLE 227. Global Disease Risk Prediction Market Size, by Country, 2017-2032 (USD Million)
TABLE 228. Global Pharmacogenomics Market Size, by Region, 2017-2032 (USD Million)
TABLE 229. Global Pharmacogenomics Market Size, by Group, 2017-2032 (USD Million)
TABLE 230. Global Pharmacogenomics Market Size, by Country, 2017-2032 (USD Million)
TABLE 231. Global Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 233. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 234. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 235. Global Clinical Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 236. Global Clinical Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. Global Clinical Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 238. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 239. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 241. Global Academic and Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 242. Global Academic and Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. Global Academic and Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 244. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 245. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 247. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 248. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 250. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 251. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 253. Global Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 254. North America Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 255. North America Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 256. North America Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
TABLE 257. North America Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
TABLE 258. North America Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
TABLE 259. North America Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
TABLE 260. North America Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 261. North America Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
TABLE 262. North America Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
TABLE 263. North America Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 264. North America Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
TABLE 265. North America Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 266. North America Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 267. North America Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 268. North America Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 269. North America Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 270. North America Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 271. North America Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
TABLE 272. North America Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
TABLE 273. North America Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. Europe Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 275. Europe Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 276. Europe Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
TABLE 277. Europe Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
TABLE 278. Europe Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
TABLE 279. Europe Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
TABLE 280. Europe Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 281. Europe Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
TABLE 282. Europe Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
TABLE 283. Europe Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 284. Europe Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
TABLE 285. Europe Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 286. Europe Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 287. Europe Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 288. Europe Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 289. Europe Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 290. Europe Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 291. Europe Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
TABLE 292. Europe Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
TABLE 293. Europe Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. Asia-Pacific Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 295. Asia-Pacific Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 296. Asia-Pacific Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
TABLE 297. Asia-Pacific Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
TABLE 298. Asia-Pacific Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
TABLE 299. Asia-Pacific Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
TABLE 300. Asia-Pacific Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 301. Asia-Pacific Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
TABLE 302. Asia-Pacific Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
TABLE 303. Asia-Pacific Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 304. Asia-Pacific Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
TABLE 305. Asia-Pacific Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 306. Asia-Pacific Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 307. Asia-Pacific Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 308. Asia-Pacific Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 309. Asia-Pacific Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 310. Asia-Pacific Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 311. Asia-Pacific Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
TABLE 312. Asia-Pacific Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
TABLE 313. Asia-Pacific Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Latin America Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 315. Latin America Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 316. Latin America Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
TABLE 317. Latin America Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
TABLE 318. Latin America Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
TABLE 319. Latin America Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
TABLE 320. Latin America Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 321. Latin America Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
TABLE 322. Latin America Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
TABLE 323. Latin America Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 324. Latin America Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
TABLE 325. Latin America Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 326. Latin America Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 327. Latin America Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 328. Latin America Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 329. Latin America Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 330. Latin America Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 331. Latin America Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
TABLE 332. Latin America Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
TABLE 333. Latin America Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
TABLE 334. Middle East Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 335. Middle East Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 336. Middle East Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
TABLE 337. Middle East Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
TABLE 338. Middle East Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
TABLE 339. Middle East Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
TABLE 340. Middle East Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 341. Middle East Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
TABLE 342. Middle East Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
TABLE 343. Middle East Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 344. Middle East Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
TABLE 345. Middle East Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 346. Middle East Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 347. Middle East Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 348. Middle East Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 349. Middle East Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 350. Middle East Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 351. Middle East Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
TABLE 352. Middle East Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
TABLE 353. Middle East Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
TABLE 354. Africa Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
TABLE 355. Africa Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 356. Africa Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
TABLE 357. Africa Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
TABLE 358. Africa Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
TABLE 359. Africa Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
TABLE 360. Africa Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
TABLE 361. Africa Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
TABLE 362. Africa Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
TABLE 363. Africa Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 364. Africa Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
TABLE 365. Africa Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
TABLE 366. Af

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Tempus AI, Inc.
  • Labcorp Holdings Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Guardant Health, Inc.
  • Revvity, Inc.
  • Myriad Genetics, Inc.
  • Caris Life Sciences, Inc.
  • NeoGenomics, Inc.
  • Quest Diagnostics Incorporated
  • Natera, Inc.
  • Eurofins Scientific SE
  • Agilent Technologies, Inc.
  • IQVIA Holdings Inc.
  • Bio-Rad Laboratories, Inc.
  • Veracyte, Inc.
  • Oxford BioDynamics Plc
  • 10x Genomics, Inc.
  • Abbott Molecular, Inc.
  • Axe Compute Inc.
  • Biodesix, Inc.
  • bioMérieux Inc.
  • BostonGene Corporation
  • Bruker Corporation
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • MDxHealth SA
  • Metabolon, Inc.
  • OncoDNA SA
  • Owkin, Inc.
  • PathAI, Inc.
  • Personalis, Inc.
  • Quanterix Corporation
  • Standard BioTools Inc.
  • Sysmex Corporation

Related Topics

Related Reports

Cancer Biomarkers Market - Global Forecast 2026-2032 - Product Image

Cancer Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Brain Biomarkers Market - Global Forecast 2026-2032 - Product Image

Brain Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Biomarkers Market - Global Forecast 2026-2032 - Product Image

Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Biomarker Testing Services Market - Global Forecast 2026-2032 - Product Image

Biomarker Testing Services Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Neurological Biomarkers Market - Global Forecast 2026-2032 - Product Image

Neurological Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.